Business context and reporting period
The supplied filing is Nanophase Technologies Corporation’s Form 10-K for the fiscal year ended December 31, 2014—not a filing identified as SOLESENCE, INC. The filing describes a single-segment developer and manufacturer of engineered nano- and sub-micron materials, serving personal care, coatings, polishing, medical diagnostics, energy, and other markets. Its common stock traded on OTCQB under NANX.
Key financial results and position
| Metric | 2014 | 2013 |
|---|---|---|
| Total revenue | $9.936 million | $9.590 million |
| Gross profit / margin | $2.831 million / 28.5% | $2.560 million / 26.7% |
| Operating loss | $1.722 million | $2.491 million |
| Net loss | $1.727 million ($0.06 per share) | $2.478 million ($0.09 per share) |
| Cash used in operating activities | $1.181 million | $0.522 million |
| Cash and cash equivalents at year-end | $1.862 million | $3.276 million |
- Revenue grew 3.6%; product revenue was $9.880 million. Cost of revenue rose to $7.105 million from $7.030 million.
- R&D expense declined to $1.338 million from $1.679 million; SG&A declined to $3.215 million from $3.372 million.
- Current assets were $3.567 million and current liabilities $0.976 million. Total liabilities were approximately $1.884 million, including $191,000 of capital lease obligations. The company reported no conventional debt.
- Capital expenditures were approximately $400,000, including a new capital lease. Stockholders’ equity was $3.846 million, down from $5.368 million.
Material changes versus 2013
- Revenue increased modestly, with growth from BASF, medical diagnostics, and polishing applications partly offset by lower revenue from a coatings customer.
- Gross margin improved, supported by production efficiencies and lower depreciation, but the company remained loss-making.
- Operating cash outflow more than doubled. The filing attributes the year-over-year change partly to working-capital movements: 2014 included about $400,000 of working-capital use, while 2013 benefited by about $800,000, primarily from receivables timing.
- Cash declined by $1.414 million during 2014. Capital lease obligations increased following equipment financing.
Outlook, risks, and unusual items
- Management expected broader customer adoption and potential incremental revenue in 2015 and beyond. Polishing orders were accelerating; energy-related products were undergoing commercial testing and qualification. These were expectations, not assured results.
- Management forecast R&D spending about 10% higher and 2015 SG&A about 8% higher, depending on project progress. Planned 2015 capital spending was $300,000–$450,000, potentially more if projects progressed successfully. Management believed available cash and possible borrowing capacity would fund operating plans through 2015.
- Customer concentration is substantial: BASF accounted for approximately 72% of 2014 revenue; the next two customers accounted for 6% and 5%. BASF agreements do not guarantee purchases and include conditions that could give BASF rights to technology and production equipment. A financial trigger includes negative trailing earnings combined with cash and certain investments below $1 million; year-end cash was $1.862 million.
- Other key risks include continued losses and cash depletion, dependence on a small customer base, long product-adoption cycles, raw-material and rare-earth supply or pricing, competition, and limited access to additional financing. The company reported an accumulated deficit of about $92.4 million and approximately $80 million of tax net operating loss carryforwards, whose use may be limited.
- Other revenue included a $56,000 fee-based project that management did not expect to recur in the foreseeable future. The filing reports no material pending legal proceedings. The independent auditor gave an unqualified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: the provided filing is for Nanophase Technologies Corporation, whereas the request metadata names SOLESENCE, INC.
- Track quarterly revenue, gross margin, operating cash use, and cash balance against management’s 2015 outlook and the $1 million BASF contract threshold.
- Monitor BASF’s share of sales, contract terms, and whether new customers and polishing or energy projects generate repeat commercial orders.
- Review capital needs, lease obligations, and the risk that additional financing may be unavailable or dilutive.
- Assess whether the reported improvement in gross margin is sustained as product mix, volumes, and raw-material costs change.